Ulcerative Colitis study: Duvakitug
Official title An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov ID: NCT07184996
What this study is testing
What is Duvakitug?
An investigational subcutaneous injectable medicine being studied as a potential treatment for ulcerative colitis.
Also referred to as SAR447189.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether duvakitug helps reduce symptoms of ulcerative colitis. It also looks at how safe the drug is.
- Who it's for
- You may be able to join if you have moderate to severe ulcerative colitis and are not already on a maintenance study.
- What's involved
- You would take duvakitug or a pretend treatment for up to 12 weeks. You will visit the clinic several times for check‑ins and tests. Some people may go through an extra 12‑week phase if they do not respond.
- Time commitment
- The study lasts up to 35 weeks, with up to 15 clinic visits for those who need the extra phase.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 to 80
You may be able to join if
- Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to \<18 years of age who meet the definition of...
- Confirmed diagnosis of moderately to severely active UC for at least 3 months prior to Baseline
- Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies
You likely can't join if
- Participants with Crohn's Disease (CD), indeterminate colitis
- Current diagnosis of Ulcerative Proctitis
- Participants with surgical bowel resection within the past 3 months prior to Baseline, or a history of \>3 bowel resections
- Prior or current high-grade gastrointestinal (GI) dysplasia
- Participants on treatment with but not on stable doses of conventional therapies prior to baseline
- Participants with prohibited medications or therapies prior to baseline
See the full eligibility criteria
- Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to \<18 years of age who meet the definition of Tanner Stage 5 for development
- Confirmed diagnosis of moderately to severely active UC for at least 3 months prior to Baseline
- Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies
- Participants with Crohn's Disease (CD), indeterminate colitis
- Current diagnosis of Ulcerative Proctitis
- Participants with surgical bowel resection within the past 3 months prior to Baseline, or a history of \>3 bowel resections
- Prior or current high-grade gastrointestinal (GI) dysplasia
- Participants on treatment with but not on stable doses of conventional therapies prior to baseline
- Participants with prohibited medications or therapies prior to baseline
- Participants with previous exposure to anti-TL1A investigational therapy The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
The study team makes the final eligibility decision.
Where it is enrolling
- Peoria, Arizona, United States
- Scottsdale, Arizona, United States
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- Arcadia, California, United States
- Canoga Park, California, United States
- Coronado, California, United States
- Folsom, California, United States
- Lancaster, California, United States
- Los Angeles, California, United States
- Murrieta, California, United States
- Oxnard, California, United States
- Sacramento, California, United States
- San Diego, California, United States
- Santa Maria, California, United States
- Tarzana, California, United States
- Thousand Oaks, California, United States
- Valencia, California, United States
- Victorville, California, United States
- Aurora, Colorado, United States
+ 177 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Peoria, Arizona, United States; Scottsdale, Arizona, United States; Tucson, Arizona, United States; Little Rock, Arkansas, United States; Arcadia, California, United States; Canoga Park, California, United States and 191 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.